Eurointervention最新文献

{"title":"Transcaval transcatheter aortic valve implantation via left-sided venous access.","authors":"Conor J Doyle, Ivan P Casserly","doi":"10.4244/EIJ-D-24-00795","DOIUrl":"10.4244/EIJ-D-24-00795","url":null,"abstract":"","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"21 12","pages":"e709-e710"},"PeriodicalIF":7.6,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12151163/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144303603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Next-day and 48-hour discharge following alternative access for transcatheter aortic valve implantation.","authors":"Yohanna John Zendo, Santiago Ordoñez, Michael W A Chu, Matthew Valdis, Siobhan Molloy, Mosa Abbadi, Patrick Teefy, Pantelis Diamantouros, Rodrigo Bagur","doi":"10.4244/EIJ-D-24-01048","DOIUrl":"10.4244/EIJ-D-24-01048","url":null,"abstract":"","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":" ","pages":"e704-e708"},"PeriodicalIF":7.6,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12151162/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144112766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One- versus three-month DAPT after everolimus-eluting stent implantation in diabetic patients at high bleeding risk: results from the XIENCE Short DAPT programme.","authors":"Angelo Oliva, Dominick J Angiolillo, Marco Valgimigli, Davide Cao, Samantha Sartori, Sripal Bangalore, Deepak L Bhatt, Gianluca Campo, Bassem M Chehab, James W Choi, Jose M de la Torre Hernandez, Yihan Feng, Junbo Ge, Mauro Gitto, James Hermiller, Mitchell W Krucoff, Vijay Kunadian, Raj R Makkar, Aziz Maksoud, Franz-Josef Neumann, Hector Picon, Shigeru Saito, Gennaro Sardella, Holger Thiele, Ralph Toelg, Olivier Varenne, Birgit Vogel, Pascal Vranckx, Stephan Windecker, Roxana Mehran","doi":"10.4244/EIJ-D-24-00897","DOIUrl":"10.4244/EIJ-D-24-00897","url":null,"abstract":"<p><strong>Background: </strong>In patients with diabetes mellitus (DM) and high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI), the optimal duration of dual antiplatelet therapy (DAPT) remains uncertain.</p><p><strong>Aims: </strong>We sought to compare early DAPT discontinuation in DM and non-DM patients enrolled in the prospective XIENCE Short DAPT programme.</p><p><strong>Methods: </strong>The effects of 1- versus 3-month DAPT on ischaemic and bleeding outcomes were compared using propensity score stratification. The primary endpoint was a composite of all-cause death or myocardial infarction (MI) at 1 year. The incidence of Bleeding Academic Research Consortium (BARC) Type 2 to 5 bleeding was the key secondary endpoint.</p><p><strong>Results: </strong>Out of 3,352 included patients, 1,299 (38.8%) had DM; diabetic patients had a higher 1-year incidence of death or MI (DM vs non-DM: 10.1% vs 6.6%) and similar BARC 2-5 bleeding (DM vs non-DM: 9.5% vs 9.2%). With 1- versus 3-month DAPT, the incidence of death or MI did not statistically differ in DM patients (adjusted hazard ratio [adjHR] 0.70, 95% confidence interval [CI]: 0.47-1.05) and non-DM patients (adjHR 1.26, 95% CI: 0.87-1.81), although heterogeneity by DM status was evident (p for interaction=0.015). BARC 2-5 bleeding was numerically lower with 1-month DAPT in both groups (DM: adjHR 0.67, 95% CI: 0.45-1.01; non-DM: adjHR 0.78, 95% CI: 0.56-1.07; p for interaction=0.973).</p><p><strong>Conclusions: </strong>Among HBR patients with DM undergoing PCI, 1-month DAPT, as compared to 3-month DAPT, was not associated with an excess of fatal or non-fatal MI and even reduced the occurrence of bleeding. These findings should be interpreted in the context of a predominantly stable patient population with low procedural complexity and may not be generalisable to higher-risk cases.</p>","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"21 12","pages":"e668-e680"},"PeriodicalIF":7.6,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12151164/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144303600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polymer-free biolimus-eluting stents: there is no such thing as a free lunch.","authors":"Raffaele Piccolo, Ernest Spitzer","doi":"10.4244/EIJ-E-25-00014","DOIUrl":"10.4244/EIJ-E-25-00014","url":null,"abstract":"","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"21 11","pages":"e592-e593"},"PeriodicalIF":7.6,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12105661/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144217600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using pericoronary fat attenuation to guide management after coronary interventions.","authors":"Charalambos Antoniades, Kenneth Chan","doi":"10.4244/EIJ-E-25-00018","DOIUrl":"10.4244/EIJ-E-25-00018","url":null,"abstract":"","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"21 11","pages":"e589-e591"},"PeriodicalIF":7.6,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12105666/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144217601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AMAC: Anchor the Mother to Advance the Child - a technique for complex PCI.","authors":"Nino Cocco, Gregor Leibundgut, Agostino Spanò, Daniel Weilennmann, Kambis Mashayekhi","doi":"10.4244/EIJ-D-24-01058","DOIUrl":"10.4244/EIJ-D-24-01058","url":null,"abstract":"","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"21 11","pages":"e649-e650"},"PeriodicalIF":7.6,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12105663/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144217594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Everolimus-eluting versus biolimus-eluting stents with biodegradable polymers in unselected patients undergoing percutaneous coronary intervention: five-year results of the randomised, non-inferiority SORT OUT VIII trial.","authors":"Nicolaj Brejnholt Støttrup, Evald Høj Christiansen, Bent Raungaard, Johnny Kahlert, Christian Juhl Terkelsen, Steen Dalby Kristensen, Troels Thim, Lars Jakobsen, Rebekka Vibjerg Jensen, Ashkan Eftekhari, Phillip Freeman, Svend Eggert Jensen, Karsten Tange Veien, Lisette Okkels Jensen, Michael Maeng, For The Scandinavian Organization For Randomized Trials With Clinical Outcome Sort Out","doi":"10.4244/EIJ-D-24-00763","DOIUrl":"10.4244/EIJ-D-24-00763","url":null,"abstract":"<p><strong>Background: </strong>Long-term outcomes following implantation of drug-eluting coronary stents are necessary to determine safety and efficacy.</p><p><strong>Aims: </strong>We aimed to report the 5-year outcomes of the SYNERGY thin-strut biodegradable-polymer everolimus-eluting platinum-chromium stent (EES) versus the BioMatrix NeoFlex biodegradable-polymer biolimus-eluting stainless-steel stent (BES).</p><p><strong>Methods: </strong>This randomised, multicentre, all-comer, non-inferiority trial was undertaken at three sites in Western Denmark. Patients with a clinical indication for percutaneous coronary intervention were eligible for inclusion. Patients were randomly assigned (1:1) to either EES or BES. Outcomes included target lesion failure (TLF: cardiac death, myocardial infarction not clearly attributable to a non-target lesion, or target lesion revascularisation), all myocardial infarctions, and very late stent thrombosis at 5-year follow-up.</p><p><strong>Results: </strong>We included 2,764 patients and randomly assigned 1,385 patients to treatment with EES and 1,379 patients to treatment with BES. TLF occurred in 150 patients (10.8%) assigned to the EES and in 165 (12.0%) assigned to the BES (rate ratio [RR] 0.88, 95% confidence interval [CI]: 0.71-1.10). The incidence of myocardial infarction was lower in the EES group (EES: n=85 [6.1%], BES: n=116 [8.4%]; RR 0.71, 95% CI: 0.54-0.95), while very late stent thrombosis was rare for both stent types (EES: n=12 [0.9%], BES: n=9 [0.7%]; RR 1.32, 95% CI: 0.56-3.14).</p><p><strong>Conclusions: </strong>At 5-year follow-up, TLF was comparable for EES and BES. The incidence of myocardial infarction, however, was lower in patients randomised to EES versus BES implantation.</p>","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"21 11","pages":"e629-e638"},"PeriodicalIF":7.6,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12105668/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144217597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A new implanter classification system for left atrial appendage closure from the European Left Atrial Appendage Closure Club (ELAACC).","authors":"Jens Erik Nielsen-Kudsk, Adel Aminian, Ole De Backer, Xavier Iriart, Sergio Berti, Roberto Galea, Xavier Freixa, Lorenz Räber, Ignacio Cruz-Gonzalez, Nina C Wunderlich, Philippe Garot","doi":"10.4244/EIJ-D-24-00954","DOIUrl":"10.4244/EIJ-D-24-00954","url":null,"abstract":"<p><p>This manuscript proposes a novel implanter classification system for left atrial appendage (LAA) closure, aimed at overcoming the limitations of current anatomical classifications. By integrating essential anatomical and functional details, this new classification system strives to provide a comprehensive framework that is both user-friendly and effective in distinguishing between complex and standard LAA anatomies, facilitating a common language among implanters and imagers, and predicting procedural risks.</p>","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"21 11","pages":"e594-e604"},"PeriodicalIF":7.6,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12105670/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144217593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Five-year outcomes of a drug-coated polymer-free biolimus-eluting stent versus an ultrathin-strut biodegradable-polymer sirolimus-eluting stent.","authors":"Lisette Okkels Jensen, Lars Jakobsen, Ashkan Eftekhari, Julia Ellert-Gregersen, Nicolaj Brejnholt Støttrup, Thomas Engstrøm, Johnny Kahlert, Philip Freeman, Karsten Tange Veien, Rebekka Vibjerg Jensen, Jens Flensted Lassen, Anders Junker, Evald Høj Christiansen","doi":"10.4244/EIJ-D-24-00586","DOIUrl":"10.4244/EIJ-D-24-00586","url":null,"abstract":"<p><strong>Background: </strong>The biolimus A9-coated polymer-free stent was not non-inferior for target lesion failure (TLF) when compared with an ultrathin-strut biodegradable-polymer sirolimus-eluting stent within 1 year in the Randomized Comparison of a Polymer-Free Biolimus-eluting BIOFREEDOM Stent With a Biodegradable-Polymer Sirolimus-eluting ORSIRO Stent in Patients Treated With Percutaneous Coronary Intervention (SORT OUT IX) trial.</p><p><strong>Aims: </strong>We aimed to assess the 5-year outcomes of the drug-coated polymer-free biolimus-eluting stent versus an ultrathin-strut biodegradable-polymer sirolimus-eluting stent.</p><p><strong>Methods: </strong>The SORT OUT IX trial was a registry-based, randomised, all-comer population trial. The primary endpoint, TLF, was defined as the composite of cardiac death, myocardial infarction (MI) not related to any segment other than the target lesion, or target lesion revascularisation (TLR) within 1 year. Follow-up was extended to 5 years.</p><p><strong>Results: </strong>A total of 3,151 patients were randomly assigned to receive either the polymer-free biolimus-coated stent (1,572 patients [1,966 lesions]) or the ultrathin-strut biodegradable-polymer sirolimus-eluting stent (1,579 patients [1,985 lesions]). Only 0.3% of participants were lost to follow-up, and all of those were due to emigration. At 5 years, TLF was 14.1% in the polymer-free biolimus-coated stent group and 12.0% in the ultrathin-strut biodegradable-polymer sirolimus-eluting stent group (rate ratio [RR] 1.19, 95% confidence interval [CI]: 0.97-1.44). Cardiac death, MI and definite stent thrombosis did not differ between the two groups. Clinically driven TLR was 7.6% versus 5.0% (RR 1.56, 95% CI: 1.17-2.07) and was higher in the polymer-free biolimus-coated stent group at 5 years, attributable to a higher risk of TLR within the first year.</p><p><strong>Conclusions: </strong>Five-year TLF did not differ significantly between the drug-coated biolimus-eluting stent group and the ultrathin-strut biodegradable-polymer stent group, but the risk of TLR was higher in the drug-coated biolimus-eluting stent group.</p>","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"21 11","pages":"e617-e628"},"PeriodicalIF":7.6,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12105667/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144217598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biodegradable-polymer versus durable-polymer drug-eluting stents in left main percutaneous coronary intervention: final results of the randomised IDEAL-LM trial.","authors":"Alexander M Griffioen, Robert-Jan M van Geuns, Margaret B McEntegart, Evgeny Merkulov, Oleg Krestyaninov, Evgeny Kretov, Maciej Lesiak, Peter O'Kane, Colm G Hanratty, Erwan Bressollette, Marc Silvestri, Adrian Wlodarczak, Paul Barragan, Richard Anderson, Aleksey Protopopov, Aaron Peace, Ian Menown, Paul Rocchiccioli, Yoshinobu Onuma, Keith G Oldroyd","doi":"10.4244/EIJ-D-24-00918","DOIUrl":"10.4244/EIJ-D-24-00918","url":null,"abstract":"","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"21 11","pages":"e639-e641"},"PeriodicalIF":7.6,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12105665/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144217595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}